Fighting cancer involves a near-impossible equation. We need your help to solve it.
Integrating with key digital and social channels, United by Cancer is powered by data, technology, and designed to connect those treating and fighting cancer. Our primary goal is to deliver personalized content and drive engagement.
ABOUT UNITED BY CANCER
Our digital platform makes it easy to learn,
connect, collaborate and support.
And to innovate on what healthcare really means.
United by Cancer: because we all care about fighting cancer.
We focus on immunology, human genetics and advanced technologies
Our Pipeline is our number one priority.
- Immuno-oncology: using the human immune system to treat cancer
- Cell therapy: engineering human T-cells to target cancer
- Cancer epigenetics: modulating the gene-regulatory system of the epigenome to exert anti-cancer effects
- Synthetic lethality: targeting two mechanisms at the same time which together, but not alone, have substantial effects against cancer
Inducible T-cell co-stimulatory receptor
A promising agent in our Oncology pipeline is the agonist immune checkpoint antibody targeting the inducible T-cell co-stimulatory receptor (ICOS) on activated T-cells. ICOS is designed to enhance a T-cell immune reaction against cancer cells. Phase I/II data, for the therapy alone and in combination with the PD-1 blocking antibody pembrolizumab (Merck), show indications of clinical activity.
Cell therapy
In the cell therapy space, we are developing the leading engineered cell therapy product for solid tumors using T cell receptors (TCRs) targeting NY-ESO-1. The therapy is engineered from the patient’s own T-cells and is currently being investigated in synovial sarcoma, lung cancer and multiple myeloma.
GSK United by Cancer connects oncologists worldwide
GSK Oncology has a commitment to the discovery and development of new oncology therapies with the life-changing potential of helping patients with cancer, specifically in four areas of cancer research: Cancer Epigenetics, Immuno-Oncology, Oncology Cell & Gene Therapy and Synthetic Lethality. Our success lies in the multiplier effect of Science × Technology × Culture. The intersection and interdependence of these three elements will deliver the next generation of medicines for patients. As Science will drive the Technology, people, from a world-wide community of experts, will drive our success in both, making our Culture a crucial component.
